<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RALOXIFENE HYDROCHLORIDE</span><br/>(ra-lox'i-feen)<br/><span class="topboxtradename">Evista<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">selective estrogen receptor antagonist/agonist</span><br/><b>Prototype: </b>Tamoxifen<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>60 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Tamoxifen analog that exhibits selective estrogen receptor antagonist activity on uterus and breast tissue. Prevents tissue
         proliferation in both sites. Decreases bone resorption and increases bone density. Decreases serum total cholesterol and LDL
         cholesterol without lowering HDL cholesterol or triglycerides.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Indicated by increased bone mineral density, lowers serum total cholesterol and LDL cholesterol.</p>
<h1><a name="uses">Uses</a></h1>
<p>Prevention and treatment of osteoporosis in postmenopausal women.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Active thromboembolic event; hypersensitivity to raloxifene; pregnancy (category X), lactation, children.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concurrent use of raloxifene and estrogen hormone replacement therapy and lipid-lowering agents.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Prevention or Treatment of Osteoporosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 mg q.d.<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Discontinue 72 h before and during prolonged immobilization.</li>
<li>Store at 15°30° C (59°86° F) in a tightly closed container and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Infection, flu-like syndrome, leg cramps, fever, arthralgia, myalgia, arthritis. <span class="typehead">CNS:</span> Migraine headache, depression, insomnia. <span class="typehead">CV:</span> <span class="speceff-common">Hot flashes</span>, chest pain, peripheral edema, decreased serum cholesterol. <span class="typehead">GI:</span> Nausea, dyspepsia, vomiting, flatulence, GI disorder, gastroenteritis, weight gain. <span class="typehead">Respiratory:</span> Sinusitis, pharyngitis, cough, pneumonia, laryngitis. <span class="typehead">Skin:</span> Rash, sweating. <span class="typehead">Urogenital:</span> Vaginitis, UTI, cystitis, leukorrhea, endometrial disorder, breast pain, vaginal bleeding. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Concomitant use of <span class="classification">estrogens</span> not recommended; absorption reduced by <b>cholestyramine.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 60% absorbed, absolute bioavailability 2%. <span class="typehead">Metabolism:</span> Extensive first-pass metabolism in liver. <span class="typehead">Elimination:</span> Excreted primarily in feces. <span class="typehead">Half-Life:</span> 27.732.5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Periodically monitor bone density, liver function, and plasma lipids; with concurrent oral anticoagulants, carefully
            monitor PT and INR.
         </li>
<li>Monitor carefully for and immediately report S&amp;S of thromboembolic events.</li>
<li>Do not give drug concurrently with cholestyramine; however, if unavoidable, space the two drugs as widely as possible.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Contact physician immediately if unexplained calf pain or tenderness occurs.</li>
<li>Avoid prolonged restriction of movement during travel.</li>
<li>Drug does not prevent and may induce hot flashes.</li>
<li>Do not take drug with other estrogen-containing drugs.</li>
<li>Tell prescriber if you are taking drugs to lower your cholesterol.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>